Thursday, January 3, 2019
Celgene downgraded to Hold from Buy at Canaccord
Canaccord analyst John Newman downgraded Celgene (CELG) to Hold from Buy and lowered his price target on the shares to $102 from $140, citing the company’s agreement to be acquired by Bristol-Myers (BMY).
https://thefly.com/landingPageNews.php?id=2843419
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.